Generic Name and Formulations:
Gadodiamide 287mg/mL; soln for IV inj.
Indications for OMNISCAN:
For use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues. For use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space.
CNS: 0.2mL/kg given as a bolus IV inj. Kidney: 0.1mL/kg. Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.2mL/kg.
CNS: 2–16yrs: 0.2mL/kg given as a bolus IV inj. Kidney: 0.1mL/kg. Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.2mL/kg.
Chronic, severe renal disease (GFR <30mL/min/1.73m2) or acute kidney injury.
Not for intrathecal use. Nephrogenic systemic fibrosis (NSF).
Not for intrathecal use; may cause convulsions, coma, sensory and motor neurologic deficits. Increased risk for nephrogenic systemic fibrosis in patients with impaired elimination of gadolinium-based contrast agents (see full labeling). Screen for acute kidney injury and other conditions that reduce renal function. Acute renal failure possible in patients with renal insufficiency within 48hrs of injection; use lowest possible dose and evaluate renal function. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. History of asthma/allergy disorders. Anaphylactoid reactions possible; have emergency equipment available. Monitor for hypersensitivity during and for several hours post-inj; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers.
Gadolinium-based contrast agent.
Interferes with serum calcium measurements with some colorimetric methods. May affect MRI.
Nausea, headache, dizziness; cardiac failure, arrhythmia, MI, anaphylaxis (may be fatal).
Vials (5mL, 10mL, 15mL, 20mL)—10; Prefilled syringe (10mL, 15mL, 20mL)—10; Prefill Plus needle-free system (15mL, 20mL)—10 (prefilled syringe + sodium chloride 0.9% inj flush syringe)
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
- Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer
- Bleeding Disorder Treatments: von Willebrand Disease
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|